Searchable abstracts of presentations at key conferences in endocrinology

ea0005p130 | Endocrine Tumours and Neoplasia | BES2003

Identification of the ACTH receptor in the human pituitary and its loss of expression in pituitary adenomas

Morris D , Kola B , Borboli N , Kaltsas G , Gueorguiev M , Jones T , Baldeweg S , Powell M , Korbonits M , Grossman A

The ACTH receptor (ACTH-R) is the second member of the melanocortin receptor family that includes five seven-transmembrane G protein-coupled receptors, and has been shown to be predominantly expressed in the adrenal cortex. It has been postulated that ACTH may regulate its own secretion through ultra-short loop feedback within the pituitary, and as ACTH-secreting adenomas are characterised by resistance to glucocorticoid feedback, they may also have dysregulated ACTH feedback....

ea0095p24 | Diabetes 1 | BSPED2023

A UK survey on the screening and management of childhood pre-clinical type 1 diabetes

Swaby Rabbi , Randell Tabitha , Scudder Claire , Bowen-Morris Jane , Townson Julia , Dayan Colin , Marcovecchio Loredana , Besser Rachel

Introduction: Type 1 diabetes (T1D) onset may start years prior to clinical presentation. Screening children and young people (CYP) for T1D using islet autoantibodies (IAb) through research studies is gaining international momentum, since screening reduces diabetic ketoacidosis, hospitalisation and offers access to drug therapies for delaying T1D onset1. Recently, ISPAD provided recommendations on monitoring for pre-clinical T1D in CYP, however no U...

ea0095p147 | Pituitary and Growth 2 | BSPED2023

Testing a screening algorithm for the identification of growth-disorders for use in UK children

Orr Joanna , Thaventhiran Thilipan , Freer Joseph , Walton Robert , Morris Joan K , Dunkel Leo , Prendergast Andrew J. , Storr Helen L.

Background: Screening algorithms for the identification of growth-disorders are routinely used in several countries. In the UK, the use of the Coventry consensus for the referral of children with suspected growth-disorders performs poorly compared to more sophisticated screening mechanisms used elsewhere. We aimed to test an algorithm developed to screen for growth-disorders in 2- to 8-year-old UK children.Methods: The a...

ea0034p41 | Clinical biochemistry | SFEBES2014

A comparison of calculated bioavailable testosterone with calculated free testosterone

Tesh David , Davies Timothy , Levy Miles , Howlett Trevor

Objective: Biochemical assessment of male hypogonadism relies on estimation of freely available testosterone. Gold standard measurement is by equilibrium dialysis but this is not practical in clinical use. We compared two calculation methods; bioavailable (non-SHBG bound) testosterone (Morris et al.), and free (non-SHBG non-albumin bound) testosterone (Vermeulen et al.) for their diagnostic performance.Design: Free testosterone and bioa...

ea0077oc4.1 | Adrenal and Cardiovascular | SFEBES2021

Development of [18F]AldoView as the first highly selective aldosterone synthase PET tracer for imaging of patients with Primary Hyperaldosteronism.

Sander Kerstin , Gendron Thibault , Cybulska Klaudia A. , Sirindil Faith , Zhou Jonhua , Kalber Tammy L. , Lythgoe Mark F. , Kurzawinski Tom R. , Brown Morris J. , Arstad Erik

Background: Inappropriately high aldosterone in patients with primary hyperaldosteronism (PHA) is due to increased aldosterone synthase (CYP11B2) activity. Selective in vivo imaging of overexpressed CYP11B2 in adrenals with positron emission tomography (PET) has not yet been achieved due to close homology of enzymes involved in aldosterone and cortisol (CYP11B1) synthesis.Aim: Synthesize a fluorine-18 labelled highly selective CYP11B2 inhibitor,...

ea0077op2.1 | Adrenal and Cardiovascular | SFEBES2021

A phase 1 clinical trial evaluating the safety and efficacy of up to two administrations of the adrenal PET tracer [18F]CETO in healthy volunteers and patients with primary aldosteronism

Senanayake Russell , Gillett Daniel , Bashari Waiel , MacFarlane James , Hu Lihua , Palma August , Aloj Luigi , Mendichovszky Iosif , Hader Stefan , Boros Istvan , Brown Morris , Cheow Heok , Aigbirhio Franklin , Gurnell Mark

Background: Primary aldosteronism (PA) is an important, potentially curable, cause of hypertension. Distinguishing unilateral and bilateral causes is a critical step in determining who should be considered for adrenalectomy. Adrenal vein sampling (AVS) remains the gold standard for lateralisation. However, AVS is technically challenging with limited availability. To address this, we have introduced molecular imaging using PET/CT with the radiotracer [11C]Metomidate ...

ea0051p002 | Thyroid | BSPED2017

Radioactive Iodine therapy for the management of hyperthyroidism in children and adolescents

Wilkinson Ingrid C E Wilkinson , Meso Muriel , Rowse Victoria , Joel Emily , Morris Elizabeth , Price Leanne , Storr Helen L , Drake William M

Background: Radioactive iodine therapy (RAI) is established as a safe and effective treatment for adults with Grave’s disease. As thyrotoxicosis in children is rare, it is difficult to obtain high quality evidence about the safety and efficacy of RAI. We present data from our centre between 2007 and 2017.Methods: 20 paediatric patients with hyperthyroidism (16F), median age 15.7 years (range 10.8–19.3) had RAI in our centre either one or two do...

ea0081oc13.1 | Oral Communications 13: Adrenal and Cardiovascular Endocrinology 2 | ECE2022

Development of [18F]AldoView as the first highly selective aldosterone synthase PET tracer for imaging of patients with primary hyperaldosteronism

Sander Kerstin , Kurzawinski Tom , Gendron Thibault , Cybulska Klaudia , Sirindil Fatih , Zhou Junhua , Kalber Tammy , Lythgoe Mark , Brown Morris , Williams Bryan , Arstad Erik

Background: Inappropriately high aldosterone in patients with primary hyperaldosteronism (PHA) is due to increased aldosterone synthase (CYP11B2) activity. Selective in vivo imaging of overexpressed CYP11B2 in adrenals with positron emission tomography (PET) has not yet been achieved due to close homology of enzymes involved in aldosterone and cortisol (CYP11B1) synthesis.Aim: Synthesize a fluorine-18 labelled highly selective CYP11B2 inhibitor, [18...

ea0091oc1 | Oral Communications | SFEEU2023

‘Pseudo-failure’ of adrenal vein sampling due to cortisol co-secretion by KCNJ5-mutant adenoma, and prediction of complete clinical success by urine hybrid steroid assay

Laycock Kate , Wu Xilin , Goodchild Emily , Matson Matthew , Prete Alessandro , Taylor Angela , Arlt Wiebke , McIntosh Alasdair , McConnachie Alexander , Cheow Heok , Drake William , Brown Morris

Case history: A previously well 45-year-old lady presented with a 3-year history of hypertension initially diagnosed at a routine health check. Her blood pressure (BP) was 170-180/90-100 mmHg.Investigations: Showed hypokalaemia (K+= 3 mmol/l; NR 3.5-5.3 mmol/l), raised aldosterone (976pmol/l; NR 100-500pmol/l) and supressed renin activity (<0.2nmol/l/h), meeting criteria for diagnosing primary aldosteronism (PA). CT adrenals showed a 2.5 cm left adre...

ea0069oc1 | Oral Communications | SFENCC2020

Biochemical and clinical cure of primary aldosteronism by ultrasound-guided endoscopic radiofrequency ablation

Goodchild Emily , Wu Xilin , Ney Alexander , Argentesi Giulia , Salsbury Jackie , O'Toole Samuel , Chung Teng-teng , Cheow Heok , Drake William , Pereira Steve , Brown Morris

A 65-year-old Afro-Caribbean gentleman, with a >10-year history of hypertension, frequently recorded blood pressures of >160/80 mmHg. His serum electrolytes showed Na+ 145 mmol/l and K+ 3.2 mmol/l. MRI demonstrated 13 mm left medial-limb adrenal adenoma. His hypertension was uncontrolled on treatment with amlodipine 10 mg OD, spironolactone 50 mg OD, losartan100 mg OD and doxazosin 16 mg OD. Although his quality of life was reduced, and he dislike...